No Data
BeiGene Reports Mixed Q1 Results; Reaffirms FY25 Outlook
BeiGene Affirms FY2025 Sales Guidance of $4.90B-$5.30B Vs $36.54B Est
BeiGene Q1 Adj. EPS $1.22 Beats $(0.74) Estimate, Sales $1.12B Miss $8.09B Estimate
Trump wants to impose tariffs on Pharmaceuticals: Pharmaceutical companies are busy stockpiling, and the import volume in the USA surged in March.
① The volume of Pharmaceutical imports in the USA surged in March, as pharmaceutical companies stockpiled products in anticipation of potential tariffs; ② A report released by the US Department of Commerce on Tuesday showed that the total value of Pharmaceutical imports in March exceeded 50 billion USD, equivalent to 20% of the total Pharmaceutical imports for the entire year of 2024.
BeiGene Q1 2025 Earnings Preview
WuXi AppTec Reports Q1 Results